Maxim Group reissued their hold rating on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a research note released on Tuesday morning, MarketBeat Ratings reports.
Other analysts have also issued research reports about the company. Ascendiant Capital Markets dropped their target price on Cyclo Therapeutics from $2.60 to $0.95 and set a buy rating on the stock in a report on Monday, August 26th. HC Wainwright reissued a neutral rating and issued a $0.95 target price (down from $3.00) on shares of Cyclo Therapeutics in a research note on Friday, August 23rd.
Check Out Our Latest Stock Report on Cyclo Therapeutics
Cyclo Therapeutics Stock Performance
Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) last released its earnings results on Thursday, August 15th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Cyclo Therapeutics had a negative net margin of 1,720.76% and a negative return on equity of 2,741.89%. The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities research analysts forecast that Cyclo Therapeutics will post -0.62 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund VI Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics makes up about 1.4% of Founders Fund VI Management LLC’s investment portfolio, making the stock its 2nd biggest position. Founders Fund VI Management LLC owned 0.48% of Cyclo Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 68.55% of the company’s stock.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.
Featured Articles
- Five stocks we like better than Cyclo Therapeutics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Most Volatile Stocks, What Investors Need to Know
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.